Cocrystal Pharma Inc reports results for the quarter ended in March - Earnings Summary

Cocrystal Pharma

13/05/2024 15:13

* Cocrystal Pharma Inc  COCP.OQ  reported a quarterly
adjusted
loss of 39 cents​​ per share for the quarter ended in March,
higher than the same quarter last year, when the company
reported EPS of -64 cents.  The mean expectation of
three analysts for the quarter was for a loss of 54 cents per
share. Wall Street expected results to range from -56 cents
to -52 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Cocrystal Pharma Inc's reported EPS for the quarter was a
loss
of 39 cents​.
    * The company reported a quarterly loss of $3.96 million.
    * Cocrystal Pharma Inc shares had risen by 23.5% this
quarter and
gained 0.4% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 17.6%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Cocrystal Pharma
Inc is $10.00 
This summary was machine generated from LSEG data May 13 at
02:13 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.54          -0.39          Beat
 Dec. 31 2023      -0.60          -0.44          Beat
 Sep. 30 2023      -0.53          -0.41          Beat
 Jun. 30 2023      -0.58          -0.41          Beat